Weekly Newsletter (9/15) Unlocking Long-Term Weight Loss: GLP-1 Medications and What You Need to Know

Topic of the Month on ModernWeight: GLP-1 Success Stories!

Head to the Social Hub to share your success story or learn about others.

AOMs in the News

This Week's Featured Post

Key Factors Impacting Long-Term Weight Loss with GLP-1 Medications

Link: ScienceDaily

In this week’s featured post, a Cleveland Clinic study published in JAMA Network Open sheds light on the key factors that affect long-term weight loss success for patients using GLP-1 receptor agonist medications, including semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza). The study followed over 3,000 adults for a year to evaluate how elements like medication type, dosage, treatment duration, and patient persistence influenced their weight loss results. Importantly, the study highlighted semaglutide's superior weight loss results compared to liraglutide.

The researchers found that higher dosages of GLP-1 medications yielded better outcomes. However, treatment persistence was identified as a crucial determinant in achieving significant weight loss. Those who stayed on the medication for the full course experienced the most meaningful results, while patients who stopped prematurely saw diminished benefits. The study emphasized the importance of continued medication use to maintain and optimize weight loss.

Why it Matters: This study highlights the critical importance of treatment persistence and the right dosage to achieve substantial and lasting weight loss. Semaglutide stands out as a highly effective medication, but consistent use over time is essential to unlock its full potential. The research provides valuable insights for healthcare providers and patients alike, underscoring the importance of setting realistic expectations and maintaining long-term treatment plans to reach weight loss goals.

GLP-1 Weight Loss Drugs Paired with Digital Health Tools Can Be More Effective

Link: Business Wire

As more Americans turn to GLP-1 weight loss medications, integrating digital health tools like Smart Meter’s iScale enhances patient outcomes. A recent study led by Stanford Medicine emphasizes that patients who closely monitor their weight and health progress using tools like digital scales and diet-monitoring platforms are more likely to achieve sustained weight loss. Smart Meter's cellular-connected weight scales transmit real-time data to healthcare providers, allowing for personalized feedback and better patient accountability.

Why it Matters: With over 15 million Americans using GLP-1 weight loss drugs, the addition of digital tools not only helps improve weight management success but also offers convenience and flexibility for both patients and healthcare providers. The real-time data ensures quicker interventions and personalized advice, which can increase the likelihood of long-term success. As healthcare becomes more data-driven, these tools provide a bridge between patients and their healthcare teams, improving outcomes.

Kourtney Kardashian’s Lemme Brand Launches Natural Weight Loss Supplements

Link: Healthline

Kourtney Kardashian’s Lemme brand is launching an “all-natural” weight loss supplement, Lemme GLP-1 Daily. Despite its name, the product doesn't contain synthetic GLP-1 hormone but instead uses natural ingredients like lemon fruit extract, saffron, and red-orange extract to promote weight loss. These ingredients are claimed to boost GLP-1 levels, curb hunger, and aid weight management.

Why it Matters: While Lemme GLP-1 Daily offers a natural approach, experts caution that these supplements are not equivalent to pharmaceutical GLP-1 receptor agonists like Ozempic and Wegovy. The effectiveness of natural ingredients for significant weight loss remains uncertain. This launch reflects the growing consumer demand for “natural” weight loss alternatives, even as medical professionals highlight the superiority of FDA-approved medications for meaningful results.

Noom Introduces $149 Compounded GLP-1 with Taper-Off Guarantee

Link: GlobeNewswire

Noom has introduced a groundbreaking $149 compounded GLP-1 weight loss medication paired with a “Taper-Off Guarantee,” designed to help users transition off the medication while maintaining their weight loss. This product addresses common challenges like poor persistence and muscle mass loss by combining the medication with Noom’s GLP-1 Companion with its Muscle Defense program.

Why it Matters: Noom’s introduction of a more affordable, compounded GLP-1 product paired with a taper-off guarantee represents a shift in the weight loss market. As prices of branded GLP-1 medications remain high, Noom’s solution offers a more accessible option with built-in long-term support, highlighting the growing demand for sustainable weight loss solutions that don't rely on lifelong medication use.

The Gut Health Crisis: Impact of GLP-1 Medications on Digestive Wellness

Link: Benefits Pro

With more Americans taking GLP-1 medications, gastrointestinal side effects such as nausea, vomiting, and constipation have become increasingly common. According to a UCLA study, up to 85% of patients using GLP-1 drugs experience digestive issues, which can affect treatment adherence. Employers offering GLP-1 medications are now grappling with the additional healthcare costs associated with managing these side effects.

Why it Matters: For patients to fully benefit from GLP-1 medications, supporting gut health is essential. Employers investing in these drugs for their employees must also consider providing comprehensive digestive health support. Without it, the effectiveness of the medication—and the return on investment—may be compromised by non-adherence due to gastrointestinal discomfort.

---

Expert Tweet of the Week

From @SOARD_JOURNAL

“Evaluation of gastric content in fasting patients during semaglutide use: an observational study - Surgery for Obesity and Related Diseases #soard24 #semaglutide #obesity”

Related Article: SOARD

Our ModernWeight "Weekly Weight Management Insights" newsletter is designed to keep you informed and engaged with the latest in weight management and GLP-1 medications. Visit the Social Hub to join the conversation and connect with our community.

Want to receive this newsletter in your inbox weekly? Create a profile!